Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp50 | Acromegaly and GH | ECE2019

Sleep disorders and cognitive dysfunction in acromegaly

Dassie Francesca , Wennberg Alexandra , Lorusso Riccardina , Parolin Matteo , Russo Lucia , Mazzocut Sara , Benavides-Varela Silvia , De Carlo Eugenio , Martini Chiara , Vettor Roberto , Semenza Carlo , Maffei Pietro

Background: In the general population, sleep disorders are associated with an increased risk of cognitive impairment; moreover, people with dementia often have sleep disturbances. The prevalence of sleep disorders, such as sleep apnea, in acromegalic patients is higher than in the general population, and they may have a higher risk of cognitive impairment due to acromegaly treatment (i.e. Radiotherapy) or cardiovascular comorbidities. In the literature, data about the relation...

ea0063p256 | Pituitary and Neuroendocrinology 1 | ECE2019

Hyperglycemia and pasireotide lar in acromegaly: a study with continuous glucose monitoring

Russo Lucia , Mazzocut Sara , Dassie Francesca , Parolin Matteo , Martini Chiara , Carlo Eugenio De , Fallo Francesco , Mioni Roberto , Vettor Roberto , Maran Alberto , Maffei Pietro

Background: Pasireotide LAR is a multireceptor targeted somatostatin analogue that has been shown to obtain a better biochemical control of acromegaly. However, pasireotide LAR could induce hyperglycemia in acromegalic patients with higher baseline glucose values. The devices that can track interstitial glucose levels such as continuous glucose monitoring (CGM) could be a useful for studying the impact of SSA on patients’ glucose status.Aim: We aime...

ea0063p1101 | Pituitary and Neuroendocrinology 3 | ECE2019

Pegvisomant: daily versus non daily administration a single centre real life study

Dassie Francesca , Rosson Marco , Parolin Matteo , Russo Lucia , Mazzocut Sara , Martini Chiara , De Carlo Eugenio , Mioni Roberto , Fallo Francesco , Vettor Roberto , Maffei Pietro

Background: Pegvisomant (PEG) is a second line medical treatment for active acromegalic patients. PEG efficacy is between 61.5 and 92% and even if it is administered daily its long half-life suggests a possible use with a non-daily regime.Aim: We aim to compare acromegalic patients on daily PEG administration (DP) with patients on non-daily PEG administration (NDP).Methods: We studied 43 acromegalic patients under PEG treatment bet...

ea0041ep903 | Pituitary - Clinical | ECE2016

Acromegalic cardiomyopathy: echocardiographic and CMR analysis

Casara Alvise , Dassie Francesca , Battocchio Marialberta , Parolin Matteo , Martini Chiara , De Carlo Eugenio , Mioni Roberto , Famoso Giulia , Tona Francesco , Fallo Francesco , Vettor Roberto , Corbetti Francesco , Maffei Pietro

Introduction: Acromegalic cardiomyopathy is characterized by myocardial hypertrophy and interstitial myocardial fibrosis at biopsy. We studied left ventricular hypertrophy -LVH- through echocardiography (-ECHO- 2-D standard echocardiography and Doppler analysis) and cardiac magnetic resonance (CMR) analysis. Myocardial fibrosis was studied with late enhancement technique (LE) and extracellular volume technique (ECV) at CMR.Methods: 25 patients -pts- (13 ...

ea0014p567 | (1) | ECE2007

Medial cerebral artery occlusion 25 years after cranial radiation therapy in acromegaly

Maffei Pietro , Martini Chiara , Barban Martina , Carli Marta , Manara Renzo , Scanarini Massimo , Mazzarotto Renzo , Meneghetti Giorgio , Menegazzo Carla , Mioni Roberto , De Carlo Eugenio , Vettor Roberto , Sicolo Nicola

Introduction: Epidemiological studies indicate that patients with acromegaly have increased mortality rates for cardiovascular and cerebrovascular disease (CVD). Potentials risk factors for increased CVD include hypopituitarism and cranial radiation therapy (CRT).Case Report: A 43-year-old acromegalic woman was admitted because of worsening headache, left lower facial numbness and left arm weakness. Two weeks later she developed a central palsy of the le...

ea0037gp.28.01 | Endocrine tumours and neoplasia – NETS | ECE2015

Clinicopathologic features, treatments, and survival of patients with ectopic Cushing's syndrome from neuroendocrine tumours: data from an Italian multicentre study

Davi Maria Vittoria , Cosaro Elisa , Piacentini Serena , Reimondo Giuseppe , Albiger Nora , Arnaldi Giorgio , Faggiano Antongiulio , Mantovani Giovanna , Fazio Nicola , Grimaldi Franco , Mannelli Massimo , Giraldi Francesca Pecori , Martini Chiara , Ferone Diego , Campana Davide , Scaroni Carla , Terzolo Massimo , DeMarinis Laura , Francia Giuseppe

Introduction: Available literature on series of patients affected by ectopic Cushing’s syndrome (ECS) deriving from neuroendocrine tumours (NETs) is relatively scarce. This is the first Italian multicentre study regarding clinicopathologic features, modalities of treatment, and survival of patients with NETs and ECS.Patients and methods: Retrospective analysis of data from patients with ECS from NETs collected in 14 centres between 1986 and 2014, ob...

ea0026p247 | Pituitary | ECE2011

A multicenter study on acromegalic patients treated with pegvisomant monotherapy or with pegvisomant plus somatostatin analogues: role of exon 3 deleted GH receptor polymorfism

Filopanti Marcello , Olgiati Luca , Lania Andrea , Beck-Peccoz Paolo , De Marinis Laura , Grottoli Silvia , Martini Chiara , Cannavo Salvatore , Bogazzi Fausto , Ferone Diego , Arnaldi Giorgio , Peri Alessandro , Tita Patrizia , Pigliaru Francesca , Angeletti Gabriella , Jaffrain-Rea Marie-Lise , Losa Marco , Spada Anna

Introduction: To date, two pharmacogenetic studies investigated the effect of the common exon 3 deletion of GH receptor (d3-GHR) variant in small series of acromegalic patients treated with Pegvisomant (Peg), suggesting an association of d3-GHR allele with better response to Peg.Aim: To assess the influence of d3-GHR variant in a large cohort of acromegalics with active disease and resistance to somatostatin analogues (SSA) treated with either Peg monoth...